These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33493355)

  • 1. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
    Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
    Shimada T; Naito R; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Kano H; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Nakagawa-Goto K; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2433-2444. PubMed ID: 37247901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft.
    Wang X; Ha D; Mori H; Chen S
    J Nutr Biochem; 2021 Mar; 89():108580. PubMed ID: 33388344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone.
    Ofude M; Mizokami A; Kumaki M; Izumi K; Konaka H; Kadono Y; Kitagawa Y; Shin M; Zhang J; Keller ET; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4453-61. PubMed ID: 24123015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models.
    Zhang ZB; Ip SP; Cho WC; Hu Z; Huang YF; Luo DD; Xian YF; Lin ZX
    J Ethnopharmacol; 2020 Oct; 260():113058. PubMed ID: 32525068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
    Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
    Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.
    Shamaladevi N; Araki S; Lyn DA; Ayyathurai R; Gao J; Lokeshwar VB; Navarrete H; Lokeshwar BL
    Oncotarget; 2016 Dec; 7(51):84201-84213. PubMed ID: 27705939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.
    Liu PY; Lin SZ; Sheu JJ; Lin CT; Lin PC; Chou YW; Huang MH; Chiou TW; Harn HJ
    Prostate; 2013 Apr; 73(5):531-41. PubMed ID: 23038474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
    Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
    Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.